Asunaprevir
Sponsors
Bristol-Myers Squibb, ANRS, Emerging Infectious Diseases, Foundation for Liver Research, Kaohsiung Medical University Chung-Ho Memorial Hospital
Conditions
Chronic Hepatitis CHepatitis CHepatitis C InfectionHepatitis C VirusHepatitis C Virus Genotype 4 InfectionHepatitis C Virus Infection
Phase 1
Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease
CompletedNCT01886599
Start: 2012-11-30End: 2013-02-28Updated: 2013-11-11
A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir
CompletedNCT02323594
Start: 2014-12-31End: 2015-02-28Updated: 2015-02-24
Phase 2
Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials
CompletedNCT01428063
Start: 2011-09-30End: 2014-12-31Updated: 2016-05-27
Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)
CompletedNCT02107365
Start: 2013-11-30End: 2015-04-30Updated: 2017-01-24
Phase 3
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
CompletedNCT01573351
Start: 2012-05-31End: 2013-12-31Updated: 2015-10-09
A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects
CompletedNCT01718145
Start: 2012-11-30End: 2014-12-31Updated: 2015-10-09
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
CompletedNCT01973049
Start: 2013-12-31End: 2014-11-30Updated: 2015-10-09
Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual
CompletedNCT01995266
Start: 2014-02-28End: 2015-07-31Updated: 2020-08-11
UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C
CompletedNCT02123654
Start: 2014-04-30End: 2015-08-31Updated: 2015-09-18
Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients
CompletedNCT02282709
Start: 2014-02-28End: 2015-07-31Updated: 2015-10-19
A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection
CompletedNCT02496078
Start: 2015-08-31End: 2017-02-28Updated: 2017-04-19
Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV
CompletedNCT03004625
Start: 2016-11-30End: 2018-04-30Updated: 2019-01-09